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Objectives: To analyze the immunogenicity of virus-like particles (VLP) of human papillo-
mavirus  type 16 (HPV16) isolated in East China and the adjuvant potential of interleukin-12
(IL-12).
Methods:  The variant HPV16 L1VLP expressed in sf9 insect cells were  puriﬁed with cesium
chloride  gradient centrifugation. BALB/c mice were vaccinated with VLP (L1N), VLP with
Freund’s  adjuvant (L1A) or VLP with IL-12 recombinant plasmid (L1P). HPV16 VLP speciﬁc
IgG  and IFN- level in the serum were detected by ELISA, and the percentage of CD4+ and
CD8+ in spleen cells was detected with ﬂow cytometry.
Results:  The titers of serum IgG antibodies in vaccinated groups were higher than in negative
control  and the serum antibodies mainly recognized conformation-dependent HPV16 VLP
epitopes.  Splenic CD4+ and CD8+ T cell subsets increased after vaccination in every experi-
mental  group, and CD8+ increased obviously in L1P group. The ratio of CD4+/CD8+ decreased
in  L1P group and increased in the other two groups, compared to control group. Vaccination
induced  speciﬁc secretion of IFN- in the serum of vaccinated group (p < 0.05), especially in
the  L1P group.Conclusions: VLP of HPV16 variant strain isolated in East China could induce humoral immu-
nity  and cellular immunity in mice, and IL-12 recombinant plasmid can enhance cellularimmunity.
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Introduction
Cervical cancer is the fourth leading cause of female tumor
mortality.1 It is estimated that 273,000 women  die from cervi-
cal  cancer every year worldwide. There is a close relationship
between cervical cancer and human papillomavirus (HPV)
infection,  especially type 16.2,3 The use of prophylactic vac-
cine  marks the great progress in preventing cervical cancer.4
Because of the region-speciﬁc HPV16 variant,5 it has not been
veriﬁed  that the current vaccine strain will be effective in all
areas.
HPV  capsid proteins have intrinsic capacity to self-
assemble into virus-like particles (VLP) in different expression
systems.  Wild-type HPV16 VLP are used for constructing the
current  HPV vaccine because they not only elicit high titers
of  protective antibody and confer protection from experi-
mental  viral challenge, but also produce a cytotoxic T-cell
response  in mice or chimpanzees.6 In addition, a random-
ized  double-blinded controlled trial demonstrated that the
bivalent  HPV16/18 L1 VLP vaccine puriﬁed from baculovirus-
infected insect cells was  generally safe, well tolerated and
highly  immunogenic.7
IL-12 is a multifunctional cytokine that plays an essential
role  in cell-mediated immunity. IL-12 not only inhibits the pro-
liferation of tumor cells in animal models but also induces the
abolition  of virus infected-cells in some conditions.8 There-
fore,  IL-12 has great potential as a vaccine adjuvant for
diseases  such as virus infection and cancer, in which cellular
immunity is crucially involved.
In this study, we  investigated the immunogenicity of VLP of
regional  (East China) variant HPV16 L1 produced in sf9 insect
cells  infected by recombinant baculovirus, and examined the
effects  on cellular immunity of combined administration of IL-
12 and VLP. The study shows that the current HPV16 variant
VLP  may  be an ideal candidate vaccine for prevent and treat
cervical  cancer in East China.
Materials  and  methods
Virus  strain
In this study we  used HPV16 variant strain isolated from a
cervical  cancer patient in East China (GenBank accession no.
AF393502).
Puriﬁcation  of  VLP
For the production of HPV16 L1 VLP, 1 × 109 sf9 cells were
grown at 27 ◦C in Grace’s insect medium (Sigma) sup-
plemented with 10% fetal calf serum, gentamycin and
amphotericin. The cells were infected with recombinant bac-
ulovirus  rBacV16 L1 at a MOI  of 10. After 72 h, the cells were
harvested by low-speed centrifugation at 1000 rpm (200 × g) for
5  min  and washed once with ice-cold phosphate buffer saline
(PBS).  All subsequent procedures were carried out at 4 ◦C. The
cell  pellet was  resuspended in one volume of PBS to a total of
24  mL  and sonicated 30 times on ice at a setting of 200 W.  The
total  cell lysate was  loaded onto a 40% (wt/vol) sucrose-PBS
cushion and centrifuged at 25,000 rpm (110,000 × g) for 2.5 h. 0 1 4;1  8(1):65–70
The  pellet was  resuspended in 7 mL  of 35% (w/v) cesium chlo-
ride  (CsCl)-PBS and centrifuged to equilibrium in 35% (wt/vol)
CsCl-PBS  for 20 h at 35,000 rpm (141,000 × g). The visible band
at  a density of 1.29 g/mL was harvested, dialyzed extensively
against PBS, concentrated with PEG 2000, and VLP was exam-
ined  with transmission electron microscopy (TEM) at 50,000
magniﬁcation. The prepared VLP was  then stored at −80 ◦C.
Plasmid
The plasmid pCAGGS-mIL-12 was  prepared by standard alka-
line  lysis and DNA was further puriﬁed by banding CsCl2
gradient centrifugation as described previously.9
Immunization  and  sampling  of  mice
Six to eight week-old female BALB/c mice were used in all
experiments. The protocols for animal experiments were
approved  by the Ethics Committee of Harbin Medical Uni-
versity.  The immunization protocols are shown in Table 1.
Plasmids  were  injected intramuscularly, while VLP and Fre-
und’s  adjuvant (Gibcol, BRL) were injected subcutaneously.
Mice serum was  obtained by retrobulbar collection two weeks
after  each immunization, when mice were  sacriﬁced with
decapitation methods. The spleen was  dissected and the size
was  measured. Single-cell suspensions were obtained from
the  spleen by gently pressing the spleen between two sterile
slides;  dissociated cells were  then washed in DMEM contain-
ing  5% fetal bovine serum (Sigma).
Flow  cytometry
Splenocytes were incubated for 30 min  at 4 ◦C with PE- or
FITC-labeled CD4+, CD8+ monoclonal antibody (Zhongshan
Biotech), followed by washing three times with PBS, then ana-
lyzed  by ﬂuorescence-activated cell sorter (FACS).
ELISA  assay
The serum concentrations of interferon- (IFN-) were
detected by using ELISA kit (Endogen) according to the manu-
facturer’s  instruction.
Detection  of  serum  IgG  antibodies
Serum IgG antibody titers were investigated using the
HPV16VLP as the target antigen in a standard ELISA. Each
well  was coated with 100 ng of puriﬁed VLP or denatured VLP
(produced  by the addition of 0.1 M DTT and boiling) in 0.05 M
sodium  carbonate buffer (pH 9.6) at 4 ◦C overnight. Plates were
then  washed four times with TBS containing 0.1% Tween 20
(TBS/T).  Non-speciﬁc binding sites in each well were  blocked
with  100 l of 1% BSA in TBS/T at 37 ◦C for 1 h. Then 100 l
of  serial 2-fold dilutions of serum were added to each well
and  incubated at 37 ◦C for 1 h. After washing, 100 l of 1:1000
HRP-conjugated goat anti-mouse IgG (Promega) were  added
and  incubated at room temperature for 1 h. Finally, the plates
were  developed by incubation with 100 l of OPD substrate
reagent (2.43 mL  0.1 M citric acid, 2.57 mL  0.2 M Na2HPO4, 5 mL
H2O, 4 mg  OPD and 15 l 30% H2O2) for 5–15 min  in the dark,
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Table 1 – The immunization protocols.
Vaccinating group First immunization (day 0) Second immunization (day 14) Third immunization (day 28)
L1N 100 l (10 g) L1 VLP + 100 l PBS 100 l (10 g) L1 VLP + 100 l PBS 100 l (10 g) L1 VLP + 100 l PBS
L1A 100 l (10 g) L1 VLP + 100 l FCA 100 l (10 g) L1 VLP + 100 l FIA 100 l (10 g) L1 VLP + 100 l FIA
L1P 100 l (10 g) L1 VLP + 100 l 100 l (10 g) L1 VLP + 100 l
CAGGS-IL-12 (100 g)
100 l (10 g) L1 VLP + 100 l
pCAGGS-IL-12 (100 g)
00 l PBS + 100 l FIA 100 l PBS + 100 l FIA
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Fig. 1 – Puriﬁed HPV16 L1 VLP. VLP were  puriﬁed from
recombinant baculovirus-infected Sf9 cells on CsCl
gradients, stained with uranyl acetate, and observed by
Considering the intrinsic capacity of HPV L1 to self-
assemble into VLP in sf9 cells, the lysates of sf9 infected with
rBacV16  L1 were  used as VLP antigen to analyze the speciﬁc
IgG  produced in L1A group (Fig. 3). ELISA results showed that
Table 2 – CD4+, CD8+ splenic lymphocyte percentages
and CD4+/CD8+ ratio in different groups after the last
immunization.
Mouse group CD4+ (%) CD8+ (%) CD4+/CD8+
L1N 37.50 ± 2.31a 13.77 ± 2.01 2.72 ± 0.41
L1A 39.38 ± 2.19a 12.92 ± 1.93 3.05 ± 0.51pCAGGS-IL-12 (100 g) p
Control 100 l PBS + 100 l FCA 1
ollowed by quenching reaction with 100 l of 3 M HCl. The
bsorbance was  read at 490 nm in an ELISA plate reader. Both
PV16  L1 monoclonal IgG CAMVIR-1 and HPV16 L1 polyclonal
ntibody M3  served as positive controls. CAMVIR-1 antibody
as  purchased from PharMingen. M3  antibody (kindly pro-
ided  by Prof. Shang, Harbin Medical University) was  collected
rom  the serum after the mice were  vaccinated with puriﬁed
PV16  L1 protein which was  expressed in bacterial strains. All
amples were examined in triplicate for each antibody class.
he  assay was  considered valid only when the coefﬁcient of
ariation  of the triplicates was  <10%. Sera with mean OD more
han  twice that of negative controls were  considered positive
or  the respective IgG subclass.
tatistical  analysis
he difference of splenic lymphocyte percentages and serum
FN-  level were  analyzed for statistical signiﬁcance (p < 0.05)
sing  SigmaStat version 10.
esults
fﬁcient  assembly  of  HPV16  L1  into  VLP
o determine whether the variant HPV16 L1 protein could self-
ssemble  efﬁciently, lysates from insect cells infected with
1  recombinant baculovirus rBacV16 L1 were  subjected to
sCl2 density gradient centrifugation and the visible band
as  analyzed by TEM. The predominant structure consisted
f  spherical particles about 50 nm in diameter with a regular
rray  of capsomeres, although smaller, larger, and irregular
pheres  were  also seen (Fig. 1). These results demonstrated
hat HPV16 L1 protein could efﬁciently self-assemble into VLP.
PV16  L1  VLP  and  adjuvant  immunity  induce  the
roliferation  of  spleen  T  lymphocytes
o monitor the development of an immune response after the
ast  immunization, spleen T lymphocytes were collected and
ubjected  to FACS. The percentage of CD4+ T lymphocytes was
ncreased  in all three immunized groups compared with the
ontrol  group. In addition, the percentage of CD8+ T lympho-
ytes  was  higher in L1P group than the other experimental
roups and L1P group had the lowest CD4+/CD8+ ratio (Table 2).
LP  induces  speciﬁc  neutralizing  antibody  in  immunized
ice
uriﬁed HPV16 L1 VLP induced speciﬁc antibody in vaccinated
ice  (Fig. 2). When mice were  given three consecutive boosterTEM.  Magniﬁcation, ×50,000.
doses, speciﬁc serum IgG responses to VLP16 increased. After
the  third immunization, IgG titers were 1:120,000 in L1N group
and  1:360,000 in L1A and L1P groups. In contrast, by ELISA
we  determined that the titers of HPV16 L1 monoclonal IgG
CAMVIR-1  (PharMingen) and polyclonal antibody M3 to puri-
ﬁed  VLP were only 1:13,500. No speciﬁc IgG was  detected in
control  group.L1P 38.25 ± 2.61a 19.17 ± 2.12a 2.00 ± 0.38
Control 31.26 ± 2.93 12.06 ± 1.70 2.59 ± 0.35
a p < 0.05, compared with control group.
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Fig. 2 – Titers of serum IgG antibodies from vaccinated
mice. L1N, L1A, L1P, control indicated sera from the
corresponding group of mice. -1, -2, -3 indicated the ﬁrst,
second  and third immunization. M3  indicated sera
antibodies from mice immunized with HPV16 L1 expressed
in  Escherichia coli. CAMVIR-1 indicated commercial HPV16
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Fig. 4 – Antibodies from vaccinated mice recognize
conﬁrmation-dependent epitopes. ELISA plates were coated
with  HPV16 L1 VLP or the denatured VLP (-denat.) andL1  monoclonal antibody.
the titers of speciﬁc IgG to the lysates of infected sf9 cells were
the  same as puriﬁed VLP. No positive results were  found for the
lysates  of normal sf9 cells. Similar results were  observed in the
other  two immunized groups.
Next we  used denatured VLP to develop ELISA for L1A group
serum  (Fig. 4). Compared to the high titers to the puriﬁed VLP
(1:360,000),  the titers of speciﬁc IgG to denatured VLP (1:13,500)
were  signiﬁcantly decreased. Similar results were  observed in
the other two immunized groups.
IL-12  promotes  cellular  immunity  responses  stimulated  by
VLP in  immunized  mice
Serum from immunized mice was  examined for the concen-
tration  of Th1-type cytokine IFN- (Table 3). Only a slight
increase in serum IFN- level was  observed in L1N group
after  three boosts, but serum IFN- level was  signiﬁcantly
boosted after three consecutive immunizations in L1P group
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Fig. 3 – Titers of sera IgG antibodies to puriﬁed VLP and
lysates  of infected Sf9 cell. L1A indicated sera from the L1A
group  of mice. -VLP indicated ELISA plate coated with VLP.
-sfvlp  indicated ELISA plate coated with lysates of Sf9 cells
infected  by rBacV16 L1. -sf. indicated ELISA plate coated
with  lysates of normal Sf9 cells.anti-sera in L1A group, M3  and CAMVIR-1 were used for
the  detection.
(799.7 pg/mL). In L1A group, after the ﬁrst immunization serum
IFN-  level increased to 190 pg/mL, but then decreased slowly
with  continued immunization. Serum IFN- level in every vac-
cination  group was higher than that in control mice (p < 0.05).
Discussion
Numerous HPV16 variants have been isolated from differ-
ent  geographic regions,5,10,11 but current HPV16 preventive
vaccine focused on a European strain.12 In the present
study, we used HPV16 variant strain isolated from a cervical
cancer  patient in East China, which was grouped into Asian-
American  type. In this study, we produced VLP of a regional
variant  HPV16 L1, and then immunized three groups of BALB/c
mice  with VLP (L1N), VLP with Freund’s adjuvant (L1A) or VLP
with  recombinant IL-12 plasmid (L1P), respectively.
ELISA assay showed that speciﬁc IgG against natural
VLP was  produced after immunization. Combination with
Freund’s  adjuvant (L1A group) or recombinant IL-12 plasmid
(L1P  group) increased IgG titers, compared to stimulation with
VLP  alone (L1N group). In either L1A or L1P group the anti-
body  titers increased with the boost interval elongated. For
denatured  VLP, IgG titers decreased signiﬁcantly compared
to  nature VLP. Notably, the titers of HPV16 L1 monoclonal
IgGCAMVIR-1 and polyclonal antibody M3 were  the same for
Table 3 – Serum IFN- level in mice vaccinated with
HPV16 L1 VLP.
Mouse
group
First immu-
nization
(pg/mL)
Second
immunization
(pg/mL)
Third immu-
nization
(pg/mL)
Control 61.9 ± 3.0 57.0 ± 2.9 58.8 ± 2.9
L1N  64.0 ± 3.5a 68.3 ± 6.7b 78.2 ± 6.2b
L1A 122.1 ± 6.8b 112 ± 7.0b 93.6 ± 6.6b
L1P 190.1 ± 11.2b 301.8 ± 12.3b 799.7 ± 21.6b
a p < 0.05 vs. control.
b p < 0.01 vs. control.
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ature or denatured VLP, suggesting that these antibodies
ecognize linear epitopes.
Although  VLP-induced neutralizing antibodies appear
ufﬁcient for the protection from experimental challenge
ith  HPV, cellular immune responses are likely to play an
mportant  role in viral clearance.13 Transient induction of
PV  speciﬁc CTL and frequent release of IFN- were detected
n  HPV16 VLP immunized chimpanzees.14 In this study, both
he  ratio of CD4/CD8+ splenic lymphocytes and serum IFN-
evel  increased in every immunized group. Enhanced IFN-
ecretion  indicates the transformation of T lymphocytes
rom Th0 to Th1. CD8+ T lymphocytes are killer cells and
he  increased ratio of CD4/CD8+ indicates the stimulation
f  cellular immune response. In the L1A group serum IFN-
evel  was  higher at the ﬁrst boost than the later boosts. We
ixed  Freund’s complete adjuvant (FCA) with VLP in the ﬁrst
oost  and Freund’s incomplete adjuvant (FIA) in the second
nd  third boosts. It is thought that FIA stimulated humoral
mmunity reaction, while FCA helped both humoral and
ellular  immunity reaction.
Our results showed that the variant HPV16 L1 VLP alone
ould  induce both mucosal and cellular immune responses,
uggesting that the VLP has the potential for being a thera-
eutic  vaccine. IL-12 is an important antitumor and antivirus
ytokine. IL-12 has been shown to be an effective adju-
ant  in several systems.15 Here we  showed that vaccinated
NA encoding IL-12 with VLP increased cellular immunity
eaction. Puriﬁed recombinant IL-12 protein as adjuvant
an  stimulate cellular immunity. However, due to its short
ife-time  a large dose of IL-12 protein is required and could
ncrease  the toxicity of IL-12. Naked DNA injection has been
eveloped  successfully for the evaluation of the antitumor
ctivity of IL-12 in animal therapy models.16–18 In this study
he  mice in L1P group were injected with VLP and IL-12
ecombinant plasmid, and they stimulated cellular reaction
fﬁciently. The percentage of CD8+ increased obviously, the
atio  of CD4+/CD8+ decreased and serum IFN- level increased
reatly. The titers of speciﬁc IgG antibodies in L1P and L1A
roups  were  similar, but there were subtype difference. IL-12
mmunity  was  associated with increased IgG2 but not IgG1.
n  addition, we  found that the spleen was  2–3 times bigger
n  L1P group than in the other groups, perhaps due to IL-12
nduced  proliferation of splenic cells.
VLP can self-reassemble after disassembling to L1 compo-
ents  in the presence of reducing agents.19 Previous studies
emonstrated that HPV16 VLP self-assembled from L1 protein
ould  encapsidate heterologous DNA up to 8.0 kb in vitro, and
he  pseudovirion can infect many  kinds of cell lines.20,21 If IL-
2  expressing plasmid DNA could be encapsidated in VLP, this
seudovirion  could be an ideal biochemical agent to be used as
 therapeutic agent for HPV infection and cervical cancer.CD4+
In summary, our study demonstrates that VLP of HPV16
ariant strain isolated in East China could induce humoral
mmunity and cellular immunity in mice, and IL-12 recom-
inant  plasmid can enhance cellular immunity.onﬂicts  of  interest
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